Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Lenvatinib (E7080/MK-7902) in Combination With Carboplatin Pemetrexed and Pembrolizumab (MK-3475) for Patients With Pretreated Advanced Non-squamous Non-small Cell Lung Cancer Harboring EGFR Mutations

NCT05258279 is registered in ClinicalTrials.gov with Juntendo University as lead sponsor.

NCT NCT05258279
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05258279 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Lenvatinib (E7080/MK-7902) in Combination With Carboplatin Pemetrexed and Pembrolizumab (MK-3475) for Patients With Pretreated Advanced Non-squamous Non-small Cell Lung Cancer Harboring EGFR Mutations
Lead sponsor
Juntendo University
Phase
Phase 2
Overall status
Completed
Start date
July 1, 2022
Completion date
October 31, 2024
Enrollment
30 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

egfr activating mutation, non-squamous non-small-cell lung cancer